港股异动 | 康方生物(09926)午前涨近3% 机构看好依沃西在一线NSCLC治疗中的巨大潜力
康方生物(09926)午前涨近3%，截至发稿，涨2.26%，报42.95港元，成交额7270.33万港元。
民生证券发布研报指出，维持康方生物“推荐”评级，公司国内销售与海外授权持续兑现，2023年实现首次盈利，预计2025年起实现持续盈利。
该行指出，7月29日，康方生物宣布，公司独立自主研发的全球首创PD-1/VEGF双抗依沃西单抗单药一线治疗PD-L1表达阳性(PD-L1TPS≥1%)的局部晚期或转移性NSCLC的新药上市申请已经获得中国国家药品监督管理局受理。依沃西成为全球迄今唯一在单药头对头III期临床中证明疗效显著优于帕博利珠单抗的药物，显著阳性结果，证明了依沃西在全球范围内的临床价值，看好依沃西在一线NSCLC治疗中的巨大潜力。同时，适应症不断扩展，看好依沃西成为全球重磅药物。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.